Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
54
UTHR Quote, Financials, Valuation and Earnings
Last price:
$472.18
Seasonality move
:
-3.02%
Day range:
$465.28 - $473.89
52-week range:
$266.98 - $519.99
Dividend yield:
0%
P/E ratio:
17.80x
P/S ratio:
7.24x
P/B ratio:
3.07x
Volume:
326.9K
Avg. volume:
437.1K
1-year change:
27.67%
Market cap:
$20.2B
Revenue:
$2.9B
EPS (TTM):
$26.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$814.8M | $7.24 | 3.27% | 9.92% | $530.84 |
|
CORT
Corcept Therapeutics, Inc.
|
$246.1M | $0.24 | 27.74% | -71.78% | $91.00 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$142M | $0.59 | 0.87% | 32.59% | $34.86 |
|
GILD
Gilead Sciences, Inc.
|
$7.7B | $1.87 | 4.32% | 94.73% | $134.53 |
|
JNJ
Johnson & Johnson
|
$24.2B | $2.46 | 6.17% | -39.04% | $212.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.4M | -$0.04 | -1.06% | -93.96% | $7.16 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$469.77 | $530.84 | $20.2B | 17.80x | $0.00 | 0% | 7.24x |
|
CORT
Corcept Therapeutics, Inc.
|
$36.31 | $91.00 | $3.8B | 41.49x | $0.00 | 0% | 5.86x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$24.13 | $34.86 | $3B | 14.08x | $0.00 | 0% | 5.30x |
|
GILD
Gilead Sciences, Inc.
|
$129.11 | $134.53 | $160.2B | 20.00x | $0.79 | 2.45% | 5.58x |
|
JNJ
Johnson & Johnson
|
$218.01 | $212.00 | $525.3B | 19.74x | $1.30 | 2.36% | 5.62x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.29 | $7.16 | $40.1M | -- | $0.00 | 0% | 4.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
-- | 1.114 | -- | 5.61x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.281 | 0.07% | 2.85x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.785 | 0.12% | 6.19x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.024 | 18.1% | 1.16x |
|
JNJ
Johnson & Johnson
|
36.62% | -0.032 | -- | 0.71x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.184 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$698.6M | $389.3M | 18.69% | 19.2% | 48.69% | $346.1M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
JNJ
Johnson & Johnson
|
$17.8B | $5.6B | 21.7% | 33.27% | 22.76% | $8B |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
United Therapeutics Corp. vs. Competitors
-
Which has Higher Returns UTHR or CORT?
Corcept Therapeutics, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 9.32%. United Therapeutics Corp.'s return on equity of 19.2% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About UTHR or CORT?
United Therapeutics Corp. has a consensus price target of $530.84, signalling upside risk potential of 13%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $91.00 which suggests that it could grow by 150.62%. Given that Corcept Therapeutics, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Corcept Therapeutics, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is UTHR or CORT More Risky?
United Therapeutics Corp. has a beta of 0.840, which suggesting that the stock is 15.965% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.804%.
-
Which is a Better Dividend Stock UTHR or CORT?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or CORT?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. United Therapeutics Corp.'s net income of $338.7M is higher than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 17.80x while Corcept Therapeutics, Inc.'s PE ratio is 41.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.24x versus 5.86x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.24x 17.80x $799.5M $338.7M CORTCorcept Therapeutics, Inc.5.86x 41.49x $207.6M $19.4M
-
Which has Higher Returns UTHR or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 35.57%. United Therapeutics Corp.'s return on equity of 19.2% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About UTHR or CPRX?
United Therapeutics Corp. has a consensus price target of $530.84, signalling upside risk potential of 13%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 44.46%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is UTHR or CPRX More Risky?
United Therapeutics Corp. has a beta of 0.840, which suggesting that the stock is 15.965% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.
-
Which is a Better Dividend Stock UTHR or CPRX?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or CPRX?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. United Therapeutics Corp.'s net income of $338.7M is higher than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 17.80x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.24x versus 5.30x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.24x 17.80x $799.5M $338.7M CPRXCatalyst Pharmaceuticals, Inc.5.30x 14.08x $148.4M $52.8M
-
Which has Higher Returns UTHR or GILD?
Gilead Sciences, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 39.21%. United Therapeutics Corp.'s return on equity of 19.2% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About UTHR or GILD?
United Therapeutics Corp. has a consensus price target of $530.84, signalling upside risk potential of 13%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $134.53 which suggests that it could grow by 4.2%. Given that United Therapeutics Corp. has higher upside potential than Gilead Sciences, Inc., analysts believe United Therapeutics Corp. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 GILDGilead Sciences, Inc.17 7 0 -
Is UTHR or GILD More Risky?
United Therapeutics Corp. has a beta of 0.840, which suggesting that the stock is 15.965% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.
-
Which is a Better Dividend Stock UTHR or GILD?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.45% to investors and pays a quarterly dividend of $0.79 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or GILD?
United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. United Therapeutics Corp.'s net income of $338.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 17.80x while Gilead Sciences, Inc.'s PE ratio is 20.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.24x versus 5.58x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.24x 17.80x $799.5M $338.7M GILDGilead Sciences, Inc.5.58x 20.00x $7.8B $3.1B
-
Which has Higher Returns UTHR or JNJ?
Johnson & Johnson has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 20.83%. United Therapeutics Corp.'s return on equity of 19.2% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B JNJJohnson & Johnson72.39% $2.10 $125.1B -
What do Analysts Say About UTHR or JNJ?
United Therapeutics Corp. has a consensus price target of $530.84, signalling upside risk potential of 13%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could fall by -2.76%. Given that United Therapeutics Corp. has higher upside potential than Johnson & Johnson, analysts believe United Therapeutics Corp. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 JNJJohnson & Johnson9 11 0 -
Is UTHR or JNJ More Risky?
United Therapeutics Corp. has a beta of 0.840, which suggesting that the stock is 15.965% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.
-
Which is a Better Dividend Stock UTHR or JNJ?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.36% to investors and pays a quarterly dividend of $1.30 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTHR or JNJ?
United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. United Therapeutics Corp.'s net income of $338.7M is lower than Johnson & Johnson's net income of $5.1B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 17.80x while Johnson & Johnson's PE ratio is 19.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.24x versus 5.62x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.24x 17.80x $799.5M $338.7M JNJJohnson & Johnson5.62x 19.74x $24.6B $5.1B
-
Which has Higher Returns UTHR or PSTV?
Plus Therapeutics, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of -316.61%. United Therapeutics Corp.'s return on equity of 19.2% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About UTHR or PSTV?
United Therapeutics Corp. has a consensus price target of $530.84, signalling upside risk potential of 13%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 2352.88%. Given that Plus Therapeutics, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Plus Therapeutics, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.8 5 0 PSTVPlus Therapeutics, Inc.3 0 0 -
Is UTHR or PSTV More Risky?
United Therapeutics Corp. has a beta of 0.840, which suggesting that the stock is 15.965% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.845, suggesting its less volatile than the S&P 500 by 15.456%.
-
Which is a Better Dividend Stock UTHR or PSTV?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or PSTV?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. United Therapeutics Corp.'s net income of $338.7M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 17.80x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.24x versus 4.68x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.24x 17.80x $799.5M $338.7M PSTVPlus Therapeutics, Inc.4.68x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Sell
27
RGC alert for Jan 22
Regencell Bioscience Holdings Ltd. [RGC] is up 40.39% over the past day.
Buy
62
BNR alert for Jan 22
Burning Rock Biotech Ltd. [BNR] is up 33.29% over the past day.
Buy
71
HYMC alert for Jan 22
Hycroft Mining Holding Corp. [HYMC] is up 17.39% over the past day.
